retatrutide type 2 diabetes phase 2 results 2024 Positive Top-line for in Diabetes: TRANSCEND-T2D-1 retatrutide type 2 diabetes phase

One trial showed participants taking 7.2mg weekly losing on average 18.7%, with many reaching 20-25% weight loss thresholds

Phase 3 data and practical implications for your protocol Phase 3 data extended the timeline to 68 weeks and pushed peak weight loss to 28.7 percent, equivalent to 71.2 pounds or 32.3 kilograms in the highest-performing participants

Abstract This retrospective cohort study aimed to elucidate the clinical significance of measuring autoantibodies against incretins in diabetes

Exenatide was found to lower the levels of high sensitivity-C-reactive protein and endothelin-1 in comparison to glargine insulin in another study [63]